AETHLON MEDICAL, INC. Patent applications |
Patent application number | Title | Published |
20140166578 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 06-19-2014 |
20140161810 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 06-12-2014 |
20130323756 | METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES - Embodiments of the present invention relate to methods, compositions and kits for quantifying exosomes. In particular, methods, composition and kits that utilize lectins to quantify exosomes are provided. | 12-05-2013 |
20130023849 | METHODS AND SYSTEMS FOR REDUCING VIRAL LOAD OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS - The present technology relates to methods and systems for the removal of pathogens and fragments thereof in hemodialysis patients. In particular, methods and systems are described where lectins can be used to remove the Hepatitis C virus and fragments thereof in hemodialysis patients, and to provide a sustained reduction in viral load. | 01-24-2013 |
20130015118 | EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 01-17-2013 |
20120037564 | METHODS AND SYSTEMS FOR REDUCING VIRAL LOAD OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS - The present technology relates to methods and systems for the removal of pathogens and fragments thereof in hemodialysis patients. In particular, methods and systems are described where lectins can be used to remove the Hepatitis C virus and fragments thereof in hemodialysis patients, and to provide a sustained reduction in viral load. | 02-16-2012 |
20110218512 | ENHANCED ANTIVIRAL THERAPY METHODS AND DEVICES - Embodiments of the present invention relate to enhanced antiviral therapy methods, devices, and kits for treating viral infections. The disclosed enhanced antiviral therapy methods, devices, and kits enhance the efficacy of an antiviral therapy by administering a lectin affinity hemodialysis treatment to an individual suffering from viral infection in combination with the antiviral therapy. | 09-08-2011 |
20110009796 | METHOD AND APPARATUS FOR INCREASING CONTAMINANT CLEARANCE RATES DURING EXTRACORPOREAL FLUID TREATMENT - An extracorporeal fluid treatment apparatus includes a separator comprising a cartridge surrounding a porous separation membrane. The membrane separates a main flow path of a cellular component of the blood from a plasma flow path. An affinity medium is disposed within the plasma flow path to bind contaminants such as viral pathogens or toxins contained within the plasma. A pump pumps the plasma through the affinity medium at an assisted flow rate preferably between 10% and 40% of the whole blood flow rate. The assisted flow rate is selected to reduce a T90% of the apparatus by at least 50% as compared to a T90% of the apparatus without the plasma pump. A method of treating blood containing contaminants includes supplying infected blood to a separator and pumping the plasma component through an affinity medium at an assisted flow rate to increase contaminant clearance. | 01-13-2011 |
20090304677 | Extracorporeal Removal of Microvesicular Particles - The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed. | 12-10-2009 |